Adina Zeki Al Hazzouri1, Michelle R Caunca2, Juan Carlos Nobrega2, Tali Elfassy2, Ying Kuen Cheung2, Noam Alperin2, Chuanhui Dong2, Mitchell S V Elkind2, Ralph L Sacco2, Charles DeCarli2, Clinton B Wright2. 1. From the Department of Public Health Sciences, Division of Epidemiology and Population Health Sciences (A.Z.A.H., M.R.C., J.C.N., T.E., R.L.S.), Evelyn F. McKnight Brain Institute (A.Z.A.H., M.R.C., N.A., C. Dong, R.L.S.), and Departments of Neurology (C. Dong, R.L.S.) and Radiology (N.A.), University of Miami Miller School of Medicine, FL; Departments of Biostatistics (Y.K.C.) and Epidemiology (M.S.V.E.), Mailman School of Public Health, and Department of Neurology, College of Physicians and Surgeons (M.S.V.E.), Columbia University, New York, NY; Department of Neurology and the Center for Neuroscience (C. DeCarli), University of California, Davis, Sacramento, CA; and National Institute of Neurological Diseases and Stroke (C.B.W.), NIH, Bethesda, MD. axz122@miami.edu. 2. From the Department of Public Health Sciences, Division of Epidemiology and Population Health Sciences (A.Z.A.H., M.R.C., J.C.N., T.E., R.L.S.), Evelyn F. McKnight Brain Institute (A.Z.A.H., M.R.C., N.A., C. Dong, R.L.S.), and Departments of Neurology (C. Dong, R.L.S.) and Radiology (N.A.), University of Miami Miller School of Medicine, FL; Departments of Biostatistics (Y.K.C.) and Epidemiology (M.S.V.E.), Mailman School of Public Health, and Department of Neurology, College of Physicians and Surgeons (M.S.V.E.), Columbia University, New York, NY; Department of Neurology and the Center for Neuroscience (C. DeCarli), University of California, Davis, Sacramento, CA; and National Institute of Neurological Diseases and Stroke (C.B.W.), NIH, Bethesda, MD.
Abstract
OBJECTIVE: We examined whether greater depressive symptoms were associated with domain-specific cognitive performance, change in cognition, and MRI markers of brain atrophy and subclinical cerebrovascular disease in a diverse sample of older adults from the Northern Manhattan Study. METHODS: Data were analyzed from the Northern Manhattan Study, a prospective cohort study of mostly Caribbean Hispanic, stroke-free, older adults. A total of 1,111 participants had baseline measures of depressive symptoms, measured as the Center of Epidemiological Studies-Depression Scale, MRI markers, and cognitive function. A Center of Epidemiological Studies-Depression score ≥16 was considered indicative of greater depressive symptoms. Multivariable linear and logistic regression models were used to examine the associations of interest. RESULTS: At baseline, 22% of participants had greater depressive symptoms. Greater depressive symptoms were significantly associated with worse baseline episodic memory in models adjusted for sociodemographic, vascular risk factor, behavioral, and antidepressive medication variables (β [95% confidence interval] = -0.21 [-0.33 to -0.10], p = 0.0003). Greater depressive symptoms were also associated with smaller cerebral parenchymal fraction (β [95% confidence interval] = -0.56 [-1.05 to -0.07], p = 0.02) and increased odds of subclinical brain infarcts (odds ratio [95% confidence interval] = 1.55 [1.00-2.42], p = 0.05), after adjustment for sociodemographic, behavioral, and vascular risk factor variables. Greater depressive symptoms were not significantly associated with white matter hyperintensity volume, hippocampal volume, or change in cognition over an average of 5 years. Results were unchanged when stabilized inverse probability weights were applied to address selective attrition during the study period. CONCLUSIONS: In this sample of mostly Caribbean Hispanic, stroke-free, older adults, greater depressive symptoms were associated with worse episodic memory, smaller cerebral volume, and silent infarcts.
OBJECTIVE: We examined whether greater depressive symptoms were associated with domain-specific cognitive performance, change in cognition, and MRI markers of brain atrophy and subclinical cerebrovascular disease in a diverse sample of older adults from the Northern Manhattan Study. METHODS: Data were analyzed from the Northern Manhattan Study, a prospective cohort study of mostly Caribbean Hispanic, stroke-free, older adults. A total of 1,111 participants had baseline measures of depressive symptoms, measured as the Center of Epidemiological Studies-Depression Scale, MRI markers, and cognitive function. A Center of Epidemiological Studies-Depression score ≥16 was considered indicative of greater depressive symptoms. Multivariable linear and logistic regression models were used to examine the associations of interest. RESULTS: At baseline, 22% of participants had greater depressive symptoms. Greater depressive symptoms were significantly associated with worse baseline episodic memory in models adjusted for sociodemographic, vascular risk factor, behavioral, and antidepressive medication variables (β [95% confidence interval] = -0.21 [-0.33 to -0.10], p = 0.0003). Greater depressive symptoms were also associated with smaller cerebral parenchymal fraction (β [95% confidence interval] = -0.56 [-1.05 to -0.07], p = 0.02) and increased odds of subclinical brain infarcts (odds ratio [95% confidence interval] = 1.55 [1.00-2.42], p = 0.05), after adjustment for sociodemographic, behavioral, and vascular risk factor variables. Greater depressive symptoms were not significantly associated with white matter hyperintensity volume, hippocampal volume, or change in cognition over an average of 5 years. Results were unchanged when stabilized inverse probability weights were applied to address selective attrition during the study period. CONCLUSIONS: In this sample of mostly Caribbean Hispanic, stroke-free, older adults, greater depressive symptoms were associated with worse episodic memory, smaller cerebral volume, and silent infarcts.
Authors: Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale Journal: Neuron Date: 2002-01-31 Impact factor: 17.173
Authors: Elizabeth Rose Mayeda; M Maria Glymour; Charles P Quesenberry; Rachel A Whitmer Journal: Alzheimers Dement Date: 2016-02-11 Impact factor: 21.566
Authors: Chuanhui Dong; Nooshin Nabizadeh; Michelle Caunca; Ying Kuen Cheung; Tatjana Rundek; Mitchell S V Elkind; Charles DeCarli; Ralph L Sacco; Yaakov Stern; Clinton B Wright Journal: Neurology Date: 2015-07-08 Impact factor: 9.910
Authors: Allison R Kaup; Amy L Byers; Cherie Falvey; Eleanor M Simonsick; Suzanne Satterfield; Hilsa N Ayonayon; Stephen F Smagula; Susan M Rubin; Kristine Yaffe Journal: JAMA Psychiatry Date: 2016-05-01 Impact factor: 21.596
Authors: R L Sacco; B Boden-Albala; R Gan; X Chen; D E Kargman; S Shea; M C Paik; W A Hauser Journal: Am J Epidemiol Date: 1998-02-01 Impact factor: 4.897
Authors: Charles DeCarli; Joseph Massaro; Danielle Harvey; John Hald; Mats Tullberg; Rhoda Au; Alexa Beiser; Ralph D'Agostino; Philip A Wolf Journal: Neurobiol Aging Date: 2005-04 Impact factor: 4.673
Authors: Mitchell S V Elkind; Robert Sciacca; Bernadette Boden-Albala; Tanja Rundek; Myunghee C Paik; Ralph L Sacco Journal: Stroke Date: 2005-11-23 Impact factor: 7.914
Authors: Taylor A James; Samuel Weiss-Cowie; Zachary Hopton; Paul Verhaeghen; Vonetta M Dotson; Audrey Duarte Journal: Psychol Bull Date: 2021-11 Impact factor: 23.027
Authors: Tomáš Formánek; Zsófia Csajbók; Katrin Wolfová; Matěj Kučera; Sarah Tom; Dag Aarsland; Pavla Cermakova Journal: Sci Rep Date: 2020-11-30 Impact factor: 4.379